about
Emerging drugs for Guillain-Barré syndromeClinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society[Immunoadsorption for steroid-unresponsive multiple sclerosis-relapses: clinical data of 14 patients].Immune mediated diseases and immune modulation in the neurocritical care unitResponse to Therapeutic Plasma Exchange as a Rescue Treatment in Clinically Isolated Syndromes and Acute Worsening of Multiple Sclerosis: A Retrospective Analysis of 90 Patients.Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential TherapeuticsInpatient management of guillain-barré syndrome.Immunotherapy of multiple sclerosis: the state of the art.Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.Plasmapheresis in neurological disorders: six years experience from University Clinical center Tuzla.A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.Hydroxyethyl starch and kidney function: A retrospective study in patients undergoing therapeutic plasma exchange.Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica.Immunoadsorption in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy with Unsatisfactory Response to First-Line TreatmentA Case of Paraneoplastic Guillain-Barré Syndrome Associated with Squamous Cell Carcinoma of the Lung
P2860
Q22241376-4E61C48D-37E6-4327-8D5D-AB3361BFD4A8Q26765172-6F9A0E6F-6033-4D0B-AB59-B9D2560FA579Q33930630-771F1A1A-0AD3-4FFB-9467-BF0FB575A9B6Q35729575-A772C9B6-7024-4BDB-B1C5-0095C9946DB4Q35921568-AEB0263A-9F6F-46D9-BE4B-C948BD4AE1D3Q36161935-0EF2FA6C-087C-42B6-8D35-E03FF6505320Q37052679-A34837FF-2890-459A-B9B8-01680B2CB230Q38083041-C730F806-F81B-43E4-B374-3B9045F7C2E0Q41447681-0A4467AD-1D19-4FC9-B061-E4395D56BF6FQ41528600-8ACEC296-38CA-42EF-82C7-89C4FCE02943Q45024832-37B9C4BD-9D82-4786-A9AC-49743BA20C85Q47586157-C034BD84-E535-414A-A58D-A2531E81BED7Q55076073-114C6DD0-8CD8-4AF3-9A24-060CE7AAFA9BQ57514622-50CBE726-8491-4CA6-90A8-09B594BEEF4BQ58564469-A5299F5F-214A-4343-96F3-76E68479C70F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasmapheresis for neurological disorders.
@en
Plasmapheresis for neurological disorders.
@nl
type
label
Plasmapheresis for neurological disorders.
@en
Plasmapheresis for neurological disorders.
@nl
prefLabel
Plasmapheresis for neurological disorders.
@en
Plasmapheresis for neurological disorders.
@nl
P2093
P2860
P356
P1476
Plasmapheresis for neurological disorders.
@en
P2093
Alexandra Schröder
Ralf A Linker
P2860
P304
P356
10.1586/ERN.09.81
P577
2009-09-01T00:00:00Z